Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Employees

528

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
05/12/25	577.30 $	-1.52%	220,906
04/12/25	586.21 $	+1.09%	219,569
03/12/25	579.89 $	+1.18%	264,717
02/12/25	573.15 $	-1.09%	290,938
01/12/25	579.45 $	-2.94%	298,162

Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

577.30USD

Average target price

563.80USD

Spread / Average Target

-2.34%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
577.30 ^USD	-1.52%		-3.30%	+87.09%

12-04	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing	MT
12-04	Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash	CI

Capitalization	13.11B 11.27B 10.56B 9.84B 18.18B 1,180B 19.77B 123B 47.68B 557B 49.21B 48.16B 2,038B	P/E ratio 2025 *	-58.8x	P/E ratio 2026 *	187x
Enterprise value	12.56B 10.8B 10.12B 9.43B 17.41B 1,131B 18.94B 118B 45.69B 534B 47.15B 46.14B 1,952B	EV / Sales 2025 *	13.2x	EV / Sales 2026 *	8.58x
Free-Float	91.44%	Yield 2025 *	-	Yield 2026 *	-

12-04	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing	MT
12-04	Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash	CI
12-04	Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals	RE
12-03	Madrigal Pharmaceuticals Insider Sold Shares Worth $2,413,416, According to a Recent SEC Filing	MT
11-21	Madrigal Pharmaceuticals Insider Sold Shares Worth $1,082,986, According to a Recent SEC Filing	MT
11-20	Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4)	RE
11-20	Madrigal Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08:30 AM
11-20	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
11-19	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT
11-10	Madrigal Pharmaceuticals, Inc. Presents New Data Demonstrating Rezdiffra®? Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated Mash Cirrhosis	CI
11-05	Sector Update: Health Care Stocks Advance Late Afternoon	MT
11-05	Sector Update: Health Care	MT
11-05	Madrigal Pharmaceuticals Shares Rise After Cantor Fitzgerald Upgrade	MT

11-20	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
11-19	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT
11-05	Madrigal Pharmaceuticals Shares Rise After Cantor Fitzgerald Upgrade	MT
11-05	Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight From Neutral	MT
11-03	Madrigal Pharmaceuticals' Liver Disease Treatment Rezdiffra Outperforms Early Cautious Outlook, BofA Says	MT

Madrigal Pharmaceuticals, Inc. Share Price

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Valuation: Madrigal Pharmaceuticals, Inc.

Chart: Madrigal Pharmaceuticals, Inc.

Latest news: Madrigal Pharmaceuticals, Inc.

Last Transcript: Madrigal Pharmaceuticals, Inc.

Analysts' recommendations: Madrigal Pharmaceuticals, Inc.

Press Releases: Madrigal Pharmaceuticals, Inc.

News in other languages: Madrigal Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Madrigal Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-30	Madrigal Pharmaceuticals : va débourser jusqu'à 2 milliards de dollars pour une molécule
07-30	USA-Les valeurs à suivre à Wall Street (actualisé)
06-20	USA-Les valeurs à suivre à Wall Street (actualisé)
19/03/24	EE.UU. - Valores a seguir en Wall Street (actualizado)
19/03/24	Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -

1 day	-1.52%
1 week	-3.30%
Current month	-3.30%
1 month	+17.99%
3 months	+33.36%
6 months	+107.49%
Current year	+87.09%

1 week	569.04	598.77
1 month	486.04	605
Current year	265	605
1 year	265	605
3 years	57.21	605
5 years	52.33	605
10 years	6.6	605

Manager	Title	Age	Since
William Sibold CEO	Chief Executive Officer	58	07/09/2023
Edward Chiang CTO	Chief Tech/Sci/R&D Officer	-	31/08/2011
Mardi Dier DFI	Director of Finance/CFO	61	10/03/2024

Director	Title	Age	Since
Paul Friedman CHM	Chairman	82	21/07/2016
Rebecca Taub BRD	Director/Board Member	73	30/06/2016
Ken Bate BRD	Director/Board Member	74	21/07/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MADRIGAL PHARMACEUTICALS, INC.	-1.52%	-3.30%	+79.93%	+757.04%	13.11B
ARGENX SE	+1.48%	+1.32%	+33.70%	+108.92%	54.89B
INSMED INCORPORATED	-0.51%	-1.81%	+170.56%	+977.65%	43.51B
WUXI APPTEC CO., LTD.	+0.90%	-0.87%	+63.71%	+14.60%	38.12B
BIONTECH SE	+0.26%	-6.69%	-20.93%	-40.82%	23.14B
GENMAB A/S	+0.32%	0.00%	+30.84%	-36.89%	19.5B
WUXI BIOLOGICS (CAYMAN) INC.	+0.98%	+3.85%	+73.37%	-40.70%	17.25B
AKESO, INC.	+0.24%	+3.15%	+87.49%	+220.62%	14.68B
SUMMIT THERAPEUTICS INC.	-2.66%	+2.35%	-1.24%	+494.48%	14.12B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.09%	+1.32%	+134.63%	-	13.78B
Average	-0.36%	-0.68%	+65.21%	+272.77%	25.21B
Weighted average by Cap.	+0.10%	-1.20%	+68.43%	+280.50%

	2025 *	2026 *
Net sales	950M 816M 765M 713M 1.32B 85.46B 1.43B 8.94B 3.45B 40.36B 3.56B 3.49B 148B	1.46B 1.25B 1.17B 1.09B 2.02B 131B 2.2B 13.72B 5.3B 61.91B 5.47B 5.35B 226B
Net income	-220M -189M -177M -165M -305M -19.83B -332M -2.08B -801M -9.37B -827M -809M -34.24B	67.78M 58.26M 54.58M 50.87M 93.96M 6.1B 102M 638M 246M 2.88B 254M 249M 10.53B
Net Debt	-549M -472M -442M -412M -762M -49.44B -828M -5.17B -2B -23.35B -2.06B -2.02B -85.38B	-613M -527M -494M -460M -850M -55.21B -925M -5.78B -2.23B -26.08B -2.3B -2.25B -95.34B